Multicenter 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus - LUNA Trial.

Trial Profile

Multicenter 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus - LUNA Trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Pasireotide (Primary)
  • Indications Lung cancer; Malignant thymoma; Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Acronyms LUNA
  • Sponsors Novartis
  • Most Recent Events

    • 06 Mar 2017 Planned End Date changed from 1 Oct 2016 to 30 Nov 2017.
    • 06 Mar 2017 Planned primary completion date changed from 1 Oct 2016 to 30 Nov 2017.
    • 11 Oct 2016 Primary endpoint has been met. (Proportion of patients progression-free at 9 months) as per results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top